Alx Oncology Holdings Inc (ALXO)

$2.03 +0.01 (0.50%)
Market Cap 271.82M
Revenue (ttm) 0.00
Net Income (ttm) -101.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.06
Volume 1,011,300
Avg Vol 1,425,148
Day's Range N/A - N/A
Shares Out 134.56M
Stochastic %K 50%
Beta 0.42
Analysts Strong Sell
Price Target $4.60

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatama...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
Bullisch_150
Bullisch_150 Jul. 8 at 8:28 AM
$ALXO today 2,70$
2 · Reply
prismmarketview
prismmarketview Jul. 7 at 3:15 PM
We are adding ALX Oncology to the PRISM Emerging Biotech Index. ALX is a clinical-stage company developing evorpacept, a CD47 inhibitor designed without an active Fc domain to enhance antibody-driven tumor clearance. New data at ESMO Breast Cancer 2026 support its CD47 biomarker strategy, showing durable responses in heavily pretreated HER2-positive metastatic breast cancer patients with high CD47 expression. A second candidate, EGFR-targeted ADC ALX2004, is in Phase 1 with initial safety data expected in the second half of 2026. $ALXO @AlxOncology https://prismmarketview.com/companies/alx-oncology-holdings-inc/
0 · Reply
MakingMoneyHere
MakingMoneyHere Jul. 6 at 6:25 PM
$ALXO After 1 month this shit will blow up
1 · Reply
Dcvfin
Dcvfin Jul. 2 at 12:40 PM
$ALXO the trial results theyre posting dont look that great. And there is a million cancer biotechs nowadays Not that exciting...
1 · Reply
MakingMoneyHere
MakingMoneyHere Jul. 2 at 6:04 AM
$ALXO
1 · Reply
focafoca99
focafoca99 Jun. 30 at 8:53 PM
$ALXO conferred an inducement stock option to its new General Counsel Michael Listgarten.
0 · Reply
MakingMoneyHere
MakingMoneyHere Jun. 30 at 6:43 AM
$ALXO https://www.onclive.com/view/cd47-expression-linked-to-durable-responses-with-zanidatamab-evorpacept-in-pretreated-her2-metastatic-breast-cancer
0 · Reply
S2K_TP
S2K_TP Jun. 27 at 12:59 PM
$RLAY $ABCL $ALXO my favorite Bio trio 🚨🔥
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 27 at 3:55 AM
$ALXO
1 · Reply
Gabriel_DS
Gabriel_DS Jun. 26 at 8:37 PM
$ALXO volume of 12M???
0 · Reply
Latest News on ALXO
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jun 30, 2026, 4:40 PM EDT - 25 days ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds

2026-06-30T12:05:28.000Z - 25 days ago

ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

Jun 30, 2026, 8:00 AM EDT - 25 days ago

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology Holdings Transcript: AGM 2026

Jun 10, 2026, 4:00 PM EDT - 6 weeks ago

ALX Oncology Holdings Transcript: AGM 2026

ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 5:30 PM EDT - 7 weeks ago

ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

Jun 1, 2026, 8:00 AM EDT - 7 weeks ago

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALX Oncology Holdings Earnings Call Transcript: Q1 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

ALX Oncology Holdings Earnings Call Transcript: Q1 2026

ALX Oncology Holdings Earnings release: Q1 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

ALX Oncology Holdings Earnings release: Q1 2026

ALX Oncology Holdings Slides: Q1 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

ALX Oncology Holdings Slides: Q1 2026

ALX Oncology Holdings Quarterly report: Q1 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

ALX Oncology Holdings Quarterly report: Q1 2026

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026, 8:00 AM EDT - 2 months ago

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology evorpacept combination data presented at ESMO congress

2026-05-07T18:42:55.000Z - 2 months ago

ALX Oncology evorpacept combination data presented at ESMO congress

JAZZ

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

May 7, 2026, 8:00 AM EDT - 2 months ago

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

ALX Oncology Holdings Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

ALX Oncology Holdings Proxy statement: Proxy filing

ALX Oncology appoints Jeff Knight as chief development, operating officer

2026-04-13T13:09:38.000Z - 3 months ago

ALX Oncology appoints Jeff Knight as chief development, operating officer

CRNX

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

Apr 13, 2026, 8:30 AM EDT - 3 months ago

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

ALX Oncology initiated with an Overweight at Wells Fargo

2026-03-19T09:55:11.000Z - 4 months ago

ALX Oncology initiated with an Overweight at Wells Fargo

ALX Oncology price target raised to $4 from $2 at H.C. Wainwright

2026-03-10T10:10:22.000Z - 4 months ago

ALX Oncology price target raised to $4 from $2 at H.C. Wainwright

ALX Oncology initiated with a Buy at UBS

2026-03-06T13:25:31.000Z - 5 months ago

ALX Oncology initiated with a Buy at UBS

ALX Oncology Holdings Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:10 AM EST - 5 months ago

ALX Oncology Holdings Transcript: TD Cowen 46th Annual Health Care Conference

ALX Oncology Holdings Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 5 months ago

ALX Oncology Holdings Slides: Corporate presentation

ALX Oncology Holdings Earnings Call Transcript: Q4 2025

Feb 27, 2026, 8:30 AM EST - 5 months ago

ALX Oncology Holdings Earnings Call Transcript: Q4 2025

ALX Oncology Holdings Annual report: Q4 2025

Feb 27, 2026, 8:30 AM EST - 5 months ago

ALX Oncology Holdings Annual report: Q4 2025

ALX Oncology Holdings Earnings release: Q4 2025

Feb 27, 2026, 8:30 AM EST - 5 months ago

ALX Oncology Holdings Earnings release: Q4 2025

ALX Oncology Holdings Slides: Q4 2025

Feb 27, 2026, 8:30 AM EST - 5 months ago

ALX Oncology Holdings Slides: Q4 2025

ALX Oncology Holdings Annual report: Q4 2025

Feb 27, 2026, 8:30 AM EST - 5 months ago

ALX Oncology Holdings Annual report: Q4 2025

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 27, 2026, 8:00 AM EST - 5 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

Feb 19, 2026, 8:33 AM EST - 5 months ago

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

Feb 19, 2026, 8:30 AM EST - 5 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

ALX Oncology price target raised to $4 from $3 at Piper Sandler

2026-02-05T11:51:50.000Z - 6 months ago

ALX Oncology price target raised to $4 from $3 at Piper Sandler

ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera

2026-01-30T13:35:41.000Z - 6 months ago

ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera

JAZZ

ALX Oncology Announces Pricing of Underwritten Offering

Jan 30, 2026, 8:30 AM EST - 6 months ago

ALX Oncology Announces Pricing of Underwritten Offering

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

Jan 30, 2026, 8:15 AM EST - 6 months ago

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

ALX Oncology Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 6 months ago

ALX Oncology Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

ALX Oncology Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 6 months ago

ALX Oncology Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

ALX Oncology Holdings Slides: Corporate presentation

Jan 15, 2026, 7:00 AM EST - 6 months ago

ALX Oncology Holdings Slides: Corporate presentation

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 11:00 AM EST - 7 months ago

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial

2026-01-08T13:55:50.000Z - 7 months ago

ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Jan 8, 2026, 8:30 AM EST - 7 months ago

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

ALX Oncology announces data from Phase 2 trial of evorpacept

2025-12-07T18:35:16.000Z - 8 months ago

ALX Oncology announces data from Phase 2 trial of evorpacept

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Dec 7, 2025, 8:00 AM EST - 8 months ago

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

ALX Oncology Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:30 AM EST - 8 months ago

ALX Oncology Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

ALX Oncology Holdings Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 8 months ago

ALX Oncology Holdings Transcript: Jefferies London Healthcare Conference 2025

ALX Oncology to Present at Upcoming Investor Conferences

Nov 18, 2025, 11:00 AM EST - 8 months ago

ALX Oncology to Present at Upcoming Investor Conferences

ALX Oncology initiated with a Buy at Jefferies

2025-11-13T14:35:58.000Z - 9 months ago

ALX Oncology initiated with a Buy at Jefferies

ALX Oncology Holdings Earnings Call Transcript: Q3 2025

Nov 7, 2025, 8:30 AM EST - 9 months ago

ALX Oncology Holdings Earnings Call Transcript: Q3 2025

ALX Oncology Holdings Quarterly report: Q3 2025

Nov 7, 2025, 8:30 AM EST - 9 months ago

ALX Oncology Holdings Quarterly report: Q3 2025

ALX Oncology Holdings Earnings release: Q3 2025

Nov 7, 2025, 8:30 AM EST - 9 months ago

ALX Oncology Holdings Earnings release: Q3 2025

ALX Oncology Holdings Slides: Q3 2025

Nov 7, 2025, 8:30 AM EST - 9 months ago

ALX Oncology Holdings Slides: Q3 2025

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 8:15 AM EST - 9 months ago

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Holdings Slides: Corporate Presentation

Nov 7, 2025, 7:00 AM EST - 9 months ago

ALX Oncology Holdings Slides: Corporate Presentation

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

Oct 30, 2025, 8:30 AM EDT - 9 months ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

ALX presents preclinical data, Phase 1 trial-in-progress for ALX2004

2025-10-23T16:45:16.000Z - 9 months ago

ALX presents preclinical data, Phase 1 trial-in-progress for ALX2004

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 9 months ago

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 10 months ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology appoints Klencke as interim CMO

2025-09-12T12:35:38.000Z - 11 months ago

ALX Oncology appoints Klencke as interim CMO

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Sep 12, 2025, 8:30 AM EDT - 11 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 29, 2025, 12:00 PM EDT - 11 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology doses first patient in Phase 1 trial for ALX2004

2025-08-19T12:10:35.000Z - 1 year ago

ALX Oncology doses first patient in Phase 1 trial for ALX2004

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 19, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology Holdings Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

ALX Oncology Holdings Earnings Call Transcript: Q2 2025

ALX Oncology Holdings Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

ALX Oncology Holdings Quarterly report: Q2 2025

ALX Oncology Holdings Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

ALX Oncology Holdings Earnings release: Q2 2025

ALX Oncology Holdings Slides: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

ALX Oncology Holdings Slides: Q2 2025

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 1 year ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 1:25 PM EDT - 1 year ago

ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 30, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Holdings Slides: Corporate Presentation

May 23, 2025, 7:00 AM EDT - 1 year ago

ALX Oncology Holdings Slides: Corporate Presentation

ALX Oncology price target lowered to $1 from $1.20 at UBS

2025-05-21T11:05:46.000Z - 1 year ago

ALX Oncology price target lowered to $1 from $1.20 at UBS

ALX Oncology Holdings Transcript: Status Update

May 20, 2025, 11:00 AM EDT - 1 year ago

ALX Oncology Holdings Transcript: Status Update

ALX Oncology Holdings Slides: Status Update

May 20, 2025, 11:00 AM EDT - 1 year ago

ALX Oncology Holdings Slides: Status Update

ALX Oncology highlights preclinical data, development plans for ALX2004

2025-05-20T12:15:50.000Z - 1 year ago

ALX Oncology highlights preclinical data, development plans for ALX2004

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 20, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology price target lowered to $2 from $5 at H.C. Wainwright

2025-05-09T10:22:29.000Z - 1 year ago

ALX Oncology price target lowered to $2 from $5 at H.C. Wainwright

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:30 AM EDT - 1 year ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Holdings Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ALX Oncology Holdings Quarterly report: Q1 2025

ALX Oncology Holdings Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

ALX Oncology Holdings Earnings release: Q1 2025

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 1:10 PM EDT - 1 year ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Apr 25, 2025, 9:00 AM EDT - 1 year ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Holdings Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

ALX Oncology Holdings Proxy statement: Proxy Filing

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:01 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology Holdings Annual report: Q4 2024

Mar 6, 2025, 9:30 AM EST - 1 year ago

ALX Oncology Holdings Annual report: Q4 2024

ALX Oncology Holdings Earnings release: Q4 2024

Mar 6, 2025, 9:30 AM EST - 1 year ago

ALX Oncology Holdings Earnings release: Q4 2024

ALX Oncology Holdings Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

ALX Oncology Holdings Registration statement: Registration Filing

ALX Oncology Holdings Transcript: Status Update

Mar 5, 2025, 9:00 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Status Update

ALX Oncology Holdings Press release: Status Update

Mar 5, 2025, 9:00 AM EST - 1 year ago

ALX Oncology Holdings Press release: Status Update

ALX Oncology Holdings Slides: Status Update

Mar 5, 2025, 9:00 AM EST - 1 year ago

ALX Oncology Holdings Slides: Status Update

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Mar 5, 2025, 8:00 AM EST - 1 year ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 8:00 AM EST - 1 year ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology Holdings Transcript: Study Update

Jan 23, 2025, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Transcript: Study Update

ALX Oncology Holdings Press release: Study Update

Jan 23, 2025, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Press release: Study Update

ALX Oncology Holdings Slides: Study Update

Jan 23, 2025, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Slides: Study Update

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Jan 21, 2025, 5:00 PM EST - 1 year ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

ALX Oncology Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

ALX Oncology Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

ALX Oncology Holdings Slides: FY 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

ALX Oncology Holdings Slides: FY 2025

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2024, 8:00 AM EST - 1 year ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Holdings Transcript: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Study Update

ALX Oncology Holdings Slides: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Holdings Slides: Study Update

ALX Oncology Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:30 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

ALX Oncology Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 4:00 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Jefferies London Healthcare Conference 2024

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 14, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Holdings Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 6:30 PM EST - 1 year ago

ALX Oncology Holdings Transcript: UBS Global Healthcare Conference 2024

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Holdings Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Quarterly report: Q3 2024

ALX Oncology Holdings Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Earnings release: Q3 2024

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 1:55 PM EDT - 2 years ago

ALX Oncology Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

ALX Oncology Holdings Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

ALX Oncology Holdings Quarterly report: Q2 2024

ALX Oncology Holdings Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

ALX Oncology Holdings Earnings release: Q2 2024

ALX Oncology Holdings Slides: Corporate Presentation

Aug 8, 2024, 4:00 PM EDT - 2 years ago

ALX Oncology Holdings Slides: Corporate Presentation

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Aug 6, 2024, 4:01 PM EDT - 2 years ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Holdings Transcript: Study Result

Jul 31, 2024, 4:30 PM EDT - 2 years ago

ALX Oncology Holdings Transcript: Study Result

ALX Oncology Holdings Press release: Study Result

Jul 31, 2024, 4:30 PM EDT - 2 years ago

ALX Oncology Holdings Press release: Study Result

ALX Oncology Holdings Slides: Study Result

Jul 31, 2024, 4:30 PM EDT - 2 years ago

ALX Oncology Holdings Slides: Study Result

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 2 years ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Holdings Transcript: Study Update

Jun 7, 2024, 1:00 PM EDT - 2 years ago

ALX Oncology Holdings Transcript: Study Update

ALX Oncology Holdings Slides: Study Update

Jun 7, 2024, 1:00 PM EDT - 2 years ago

ALX Oncology Holdings Slides: Study Update

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Jun 2, 2024, 10:00 AM EDT - 2 years ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 29, 2024, 9:00 AM EDT - 2 years ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:00 PM EDT - 2 years ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Holdings Quarterly report: Q1 2024

May 9, 2024, 3:00 AM EDT - 2 years ago

ALX Oncology Holdings Quarterly report: Q1 2024

ALX Oncology Holdings Earnings release: Q1 2024

May 9, 2024, 3:00 AM EDT - 2 years ago

ALX Oncology Holdings Earnings release: Q1 2024

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 7, 2024, 9:00 AM EDT - 2 years ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Holdings Proxy statement: Proxy Filing

May 2, 2024, 8:00 AM EDT - 2 years ago

ALX Oncology Holdings Proxy statement: Proxy Filing

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 2 years ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Bullisch_150
Bullisch_150 Jul. 8 at 8:28 AM
$ALXO today 2,70$
2 · Reply
prismmarketview
prismmarketview Jul. 7 at 3:15 PM
We are adding ALX Oncology to the PRISM Emerging Biotech Index. ALX is a clinical-stage company developing evorpacept, a CD47 inhibitor designed without an active Fc domain to enhance antibody-driven tumor clearance. New data at ESMO Breast Cancer 2026 support its CD47 biomarker strategy, showing durable responses in heavily pretreated HER2-positive metastatic breast cancer patients with high CD47 expression. A second candidate, EGFR-targeted ADC ALX2004, is in Phase 1 with initial safety data expected in the second half of 2026. $ALXO @AlxOncology https://prismmarketview.com/companies/alx-oncology-holdings-inc/
0 · Reply
MakingMoneyHere
MakingMoneyHere Jul. 6 at 6:25 PM
$ALXO After 1 month this shit will blow up
1 · Reply
Dcvfin
Dcvfin Jul. 2 at 12:40 PM
$ALXO the trial results theyre posting dont look that great. And there is a million cancer biotechs nowadays Not that exciting...
1 · Reply
MakingMoneyHere
MakingMoneyHere Jul. 2 at 6:04 AM
$ALXO
1 · Reply
focafoca99
focafoca99 Jun. 30 at 8:53 PM
$ALXO conferred an inducement stock option to its new General Counsel Michael Listgarten.
0 · Reply
MakingMoneyHere
MakingMoneyHere Jun. 30 at 6:43 AM
$ALXO https://www.onclive.com/view/cd47-expression-linked-to-durable-responses-with-zanidatamab-evorpacept-in-pretreated-her2-metastatic-breast-cancer
0 · Reply
S2K_TP
S2K_TP Jun. 27 at 12:59 PM
$RLAY $ABCL $ALXO my favorite Bio trio 🚨🔥
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 27 at 3:55 AM
$ALXO
1 · Reply
Gabriel_DS
Gabriel_DS Jun. 26 at 8:37 PM
$ALXO volume of 12M???
0 · Reply
MakingMoneyHere
MakingMoneyHere Jun. 25 at 8:25 PM
$ALXO Guys, don't worry yet! Last summer after market hours the stock dropped from 45 cents to 30 cents and then went up to $2 in a month and a half 🤣
0 · Reply
StarJ7
StarJ7 Jun. 25 at 8:06 PM
$ALXO
0 · Reply
Gabriel_DS
Gabriel_DS Jun. 25 at 8:04 PM
$ALXO what just happened? Can't find any news
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 25 at 2:49 PM
$ALXO There it goes I told u.. Patience.. Another winner
1 · Reply
MakingMoneyHere
MakingMoneyHere Jun. 25 at 8:28 AM
$ALXO
0 · Reply
MakingMoneyHere
MakingMoneyHere Jun. 23 at 9:05 AM
$ALXO -17% premarket, what the fc 🤣
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 4 at 8:10 PM
$ALXO Still down a little on this one. I got time for $2.00 big money 💰
0 · Reply
MarketBeat
MarketBeat Jun. 4 at 3:04 AM
https://marketbeat.com/a/8691213/ $ALXO ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
0 · Reply
No_CacaWewe_Stock
No_CacaWewe_Stock Jun. 3 at 3:51 PM
$ALXO 🖕🏿🩳😡
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 3 at 1:41 PM
$ALXO Adds!!
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Jun. 3 at 9:59 AM
$ALXO $1.87 Next major resistance has a lot to break before $2.00 then it should get easy 🍳
0 · Reply
RobertoVPA
RobertoVPA May. 28 at 4:54 PM
$ALXO Wall Street analysts' consensus remains unanimously "Buy," with average price targets above $4.30 (more than double the current value). Seeing a stock stagnate can be boring, but in biotech, "no movement" equates to stability. It's a sign that no one is running away and that strong hands are simply waiting for medical advances in the coming months.🙂
2 · Reply